Entero Healthcare Solutions Ltd

- There is no explicit mention of any current or upcoming fundraising through debt or equity in the provided transcript. - The company has around Rs. 280 crores of unutilized funds, including Rs. 45 crores earmarked for inorganic growth (acquisitions). - Management indicated they will continue acquisitions using internal accruals and available funds, suggesting no immediate plans for external fundraising. - The focus is on margin improvement and working capital optimization to fund growth internally. - No references to new debt or equity issuance were made during the Q&A or management comments.

- The company has multiple ongoing acquisitions; 9 acquisitions have been completed in FY25, contributing Rs. 750 crores in annualized revenue. - Full impact of these acquisitions is expected to reflect from Q3 FY25 onwards, with continued strategic inorganic growth planned. - Prabhat Agrawal mentioned pursuing margin-accretive acquisitions, focusing on expanding geography and product categories like specialty pharma, medical devices, diagnostic equipment, and surgical consumables. - Rs. 280 crores of unutilized funds (including Rs. 45 crores earmarked for acquisitions) remain available for future acquisitions. - The acquisition pace is expected to continue through FY25 and FY26, targeting another Rs. 1,000 crores of acquisitions next year. - There are investments in operational efficiencies and talent to integrate acquisitions and prepare for future growth. - HealthEdge platform investment to connect retail pharmacies with warehouses through technology to improve market competition and wallet share.

- Targeting 35% revenue growth for the current financial year (FY25), with organic growth at approximately 15% in H1 and expected full-year organic growth at 1.5-2 times the market growth rate (~8% market growth). - Inorganic growth to contribute significantly, with completed acquisitions adding Rs. 750 crores in annualized revenue, and total acquisition targets of around Rs. 1,000 crores for FY25 and a similar target planned for FY26. - Expect the full impact of acquisitions to be realized primarily in H2 FY25, making second-half numbers lumpy but stronger. - Expanding reach covering around 500 of 750 districts and increasing retailer coverage from 63,000-65,000 to around 80,000 retailers. - Focus on increasing wallet share and geographical expansion, including new product categories like medical devices, diagnostic equipment, and surgical consumables. - Pursuing margin-accretive acquisitions selectively, with no plans to slow acquisition pace in FY25 and FY26.

- Guidance for FY25 revenue growth is maintained at 35%-40%. - EBITDA margin target of around 4% by end of Q4 FY25, up from 3.3% in Q2 FY25, implying a 70 basis points expansion through a combination of gross margin improvements and operating leverage. - Expect consistent quarter-on-quarter margin expansion driven by high-margin acquisitions and operational efficiencies. - Profit after tax significantly increased (300% YoY in H1 FY25), reflecting strong margin improvement and optimized finance costs. - Operating cash flow expected to turn positive driven by margin expansion and reduction in working capital cycle. - Earnings growth supported by both organic growth (~15% in H1 FY25) and inorganic growth via acquisitions. - Acquisition strategy to continue at current intensity, supporting further growth from FY25 onwards. - EPS expected to improve commensurately with EBITDA and PAT growth.

The transcript does not explicitly mention current or expected order book or pending orders details for Entero Healthcare Solutions Limited. However, some relevant points related to future growth and acquisitions include: - The company targets Rs. 1,000 crore worth of acquisitions for FY25 and plans to pursue a similar amount for FY26. - Multiple acquisitions completed in FY25 have contributed to inorganic growth, with more acquisitions expected every quarter. - The full impact of acquisitions done in the first half will reflect in the second half. - Expansion plans include increasing geographic reach and product categories through acquisitions. - The company sees continued opportunities in the market and does not expect the pace of acquisitions to slow down through FY26. - No specific numbers related to order book or pending orders were disclosed in the call.